VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

ALVAC-MV-HA/F
Vaccine Information
  • Vaccine Ontology ID: VO_0004741
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • F fusion protein gene engineering:
    • Type: Recombinant vector construction
    • Description: Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992).
    • Detailed Gene Information: Click Here.
  • H hemagglutinin protein gene engineering:
    • Type: Recombinant vector construction
    • Description: Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992).
    • Detailed Gene Information: Click Here.
  • Preparation: Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Dog Response

  • Vaccination Protocol: Vaccinate the dogs with recombinant vaccine (Taylor et al., 1992).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Lethal does of canine distember virus (CDV) (Taylor et al., 1992).
  • Efficacy: The recombinants elicited a protective immune response. The level of MV neutralizing antibodies and the level of protection induced against CDV challenge achieved by the host-restricted CPV vector were equivalent to that obtained by vaccinia virus vectors expressing the same MV antigens (Taylor et al., 1992).
References